Pharma · Private company
Janssen-Cilag Ltd.
Track this companyFree. Adds Janssen-Cilag Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- GuselkumabPhase 3 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GuselkumabPhase 3 · Fistulizing Crohns DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ustekinumab 90 mg (SC) Group 1Phase 3 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ustekinumab 90 mg (SC) Group 2Phase 3 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Ustekinumab approximately 6 mg/kg (IV)Phase 3 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- No interventionMultiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 17, 2024ClinicalTrials.gov NCT06408935 · fetched Nov 12, 2026
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Sep 27, 2022ClinicalTrials.gov NCT05347095 · fetched Nov 12, 2026
- A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody TreatmentCOMPLETED · started Aug 2, 2019ClinicalTrials.gov NCT04035226 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · COMPLETED · started Dec 20, 2018ClinicalTrials.gov NCT03782376 · fetched Nov 12, 2026